EGFR/HDAC-IN-2
EGFR/HDAC-IN-2 (Compound 38) is dual-functional inhibitor of EGFR and HDAC3 with IC50s of 20.34 and 1.09 nM for CDK9 and HDAC3, respectively. EGFR/HDAC-IN-2 has superior anti-proliferative activity against cancer cells, inhibits cell migration and induces late-stage cell apoptosis. EGFR/HDAC-IN-2 significantly inhibits triple-negative breast cancer (TNBC) tumor growth in xenograft mouse models. EGFR/HDAC-IN-2 can be used for cancers like TNBC research[1].
Product Specifications
UNSPSC
12352101
Target
Apoptosis; EGFR; HDAC
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=C(NCC1=CC=CC(F)=C1)C2=CC=C(NC(C3=CC=CC=C3F)=O)C=C2F
Molecular Formula
C21H15F3N2O2
Molecular Weight
384.35
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
EGFR/ErbB1/HER1; HDAC3
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Dictyoglomus thermophilum UvrABC system protein C (uvrC), partial
